BRAIN Biotech AG: Additional CRISPR Genome Editing Nucleases Identified

DGAP-News: BRAIN Biotech AG / Key word(s): Miscellaneous
15.07.2021 / 11:00
The issuer is solely responsible for the content of this announcement.

Zwingenberg (Germany), July 15^th, 2021

Additional CRISPR Genome Editing Nucleases Identified

• Around 2,000 Class 2 CRISPR Nucleases identified
• Selective additional IP protection filed
• Partnering discussions started

BRAIN Biotech AG has identified around 2,000 so far untapped additional Class 2 CRISPR Nucleases using metagenomics sequencing which could be deployed for genome editing. With a focused investment approach the company has so far analyzed a limited number in detail and has already filed a first IP protection for 15 nucleases. BRAIN recently selected and announced a prime candidate, the so-called BRAIN Engineered Cas Nuclease (BEC), which is already applied in different organisms and projects.

In addition, the company has started initial partnering discussions and is open for further partners to accelerate the detailed screening of its further promising CRISPR Nuclease candidates.

Dr. Paul Scholz, heading the Cas nuclease discovery program at BRAIN Biotech AG states: "The now identified Class 2 CRISPR Nucleases will give us a strong basis to develop a broader diversity of genome editing tools. Science requires a choice of adequate tools for different applications. Genome editing is a very exciting enabling technology for many biotechnology innovations. We are very pleased that BRAIN can now make a strong contribution to the evolution of genome editing."

Dr. Michael Krohn, Head R&D at BRAIN Biotech AG says: "We are expanding our footprint in genome editing. This will enable us to secure a broader IP position and to diversify our toolset. Together with partners we will accelerate this development and mobilize significantly larger financial and scientific resources. We are very excited to jointly advance in genome editing with our future partners."

About BRAIN

BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

Contact Investor Relations
Michael Schneiders
Head of Investor Relations & Sustainability
Phone: +49 6251 9331-86
Email: mis@brain-biotech.com

Media Contact
Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.

Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.

BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)

15.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de